Real-World Effectiveness and Safety of Tildrakizumab in Patients With Moderate-to-Severe Psoriasis After Failure of Ustekinumab: A Multicenter Retrospective Study.
Sergio Santos-Alarcón, Javier Mataix Díaz, Luca Schneller‐Pavelescu, Isabel Belinchon et autres
OBJECTIVE: To evaluate the effectiveness and safety of switching to tildrakizumab, a selective interleukin (IL) 23p19 inhibitor, in patients with moderate-to-severe plaque psoriasis who had an inadequate response to ustekinumab (IL-12/23 inhibitor) in a real-world setting. METHODS: A multicenter retrospective observational study …
es (code pays fourni par la source)